Med. praxi. 2025;22(3):181-186 | DOI: 10.36290/med.2025.048

Hereditary angioedema and its differential diagnosis

MUDr. Irena Krčmová, CSc.
Ústav klinické imunologe a alergologie, FN Hradec Králové, LF UK Hradec Králové

Angioedema is swelling involving the subcutaneous and/or submucosal layers of tissue that affects the face, lips, neck and extremities, oral cavity, larynx, and/or intestinal mucosa. The differential diagnosis of angioedema is interdisciplinary. From a pathophysiological perspective, angioedema can be classified as histamine-mediated angioedema and bradykinin-mediated angioedema. Histamine-mediated angioedema is more common and is associated with activation and degranulation of mast cells and basophils, and is often accompanied by pruritic and erythematous urticaria. Bradykinin-mediated angioedema can include forms of hereditary angioedema, acquired C1 inhibitor deficiency, and angioedema associated with angiotensin-converting enzyme inhibitors or other drugs. It is characterized by excessive local production of bradykinin with the development of painful angioedema, is not associated with pruritic urticaria, has a longer duration, and often has abdominal symptoms. It is resistant to standard therapies such as adrenaline, glucocorticoids, and antihistamines. As part of the differential diagnosis in the acute phase, it is appropriate to perform a laboratory test for tryptase to differentiate histamine angioedema in conjunction with anaphylaxis and the C4 component of complement as a screening for bradykinin angioedema. Hereditary angioedema (HAE) is a rare, genetically determined disease with autosomal dominant transmission and a variable spectrum of bradykinin angioedema. In a broader context, it is an immunodeficiency disease, classified into HAE with C1 inhibitor deficiency (HAE-C1-INH) and HAE with normal levels and function of C1 inhibitor (HAE nC1-INH), with mutations of another (often still unknown) type. The establishment of centers for the diagnosis and care of patients with HAE and acquired bradykinin angioedema (AAE) has significantly improved the lives of these patients. Patients with atypical angioedema (with a predominance of bradykinin etiology) are also referred to the centers.

Keywords: hereditary angioedema, diagnostics, differential diagnostics, therapy.

Received: April 29, 2025; Revised: May 28, 2025; Accepted: May 28, 2025; Published: June 26, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krčmová I. Hereditary angioedema and its differential diagnosis. Med. praxi. 2025;22(3):181-186. doi: 10.36290/med.2025.048.
Download citation

References

  1. . Krčmová I. Hereditární angioedém - klasifikace a diferenciální diagnostika Čes-slov Derm. 2024;99(3):115-124.
  2. . Sobotková M. Angioedémy - a jak na ně. Alergie. 2025;148:44-51.
  3. . Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382:1136-1148. Go to original source... Go to PubMed...
  4. . Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3. doi: 10.1016/j.jaip.2020.08.046. Epub 2020 Sep 6. PMID: 32898710. Go to original source... Go to PubMed...
  5. . Sobotková M, Králíčková P, et al. Hereditární angioedém. Praha: Current media s. r. o. 2021.
  6. . Reshef A, Buttgereit T, Betschel SD, et al. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J Allergy Clin Immunol. 2024 Aug;154(2):398-411.e1. doi: 10.1016/j.jaci.2024.03.024. Epub 2024 Apr 25. PMID: 38670233. Go to original source... Go to PubMed...
  7. . Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema -The 2021 revision and update. Allergy. 2022;77:1961-1990. https://doi.org/10.1111/all.15214. Go to original source... Go to PubMed...
  8. . Settipane RA, Bukstein D, Riedl M. Shared decision making in HAE management. Allergy Asthma Proc. 2020; 41:S55-S60. Go to original source... Go to PubMed...
  9. . Malbrán A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol. 2014 Aug;177(2):544-53. doi: 10.1111/cei.12358. PMID: 24749847; PMCID: PMC4226605. Go to original source... Go to PubMed...
  10. . Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy. 2022 Mar;77(3):979-990. doi: 10.1111/all.15011. Epub 2021 Aug 13. PMID: 34287942; PMCID: PMC9292251. Go to original source... Go to PubMed...
  11. . Watt M, Malmenäs M, Romanus D, et al. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema. J Comp Eff Res. 2023 Jun;12(6):e220188. doi: 10.57264/cer-2022-0188. Epub 2023 May 23. PMID: 37218553; PMCID: PMC10402909. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.